Perception is 155,012 evidence snippets — reviews, video, forums, articles — each scored for sentiment, emotional register and voice. The English-language cannabis conversation is largely shared between the two countries; where a voice is country-specific below, it is labelled. All quotes verbatim.
Patients — relief and reality
"I have had the best sleep in years since I began using them." — review "Great for my nerve pain 10/10" — review "I tried to go to sleep but kept waking up with heart palpitations." — review
The positive sleep/anxiety/pain conversation is large and experientially real; the negative tail (palpitations, grogginess, no effect) is smaller but persistent. This is a market powered by testimony, not trials.
Clinicians — the opioid-alternative argument
"We made a big point to use cannabis instead of opiates… cannabis also has a very, very important role in end-of-life care." — YouTube (palliative clinician)
Clinical enthusiasm concentrates where the evidence is: the licensed indications and opioid-sparing. Regulatory caution is equally on the record:
"We found no evidence any form of cannabis is effective in treating anxiety, depression or post-traumatic stress disorder." — UK review, quoted in corpus
The licensed core — what cannabis is actually for, medically
- Epidyolex (cannabidiol) — severe childhood epilepsies (Dravet, Lennox-Gastaut). The corpus carries the trial literature: in one study, 85% of CBD-treated epilepsy patients showed sleep improvement.
- Sativex / nabiximols (THC:CBD) — multiple-sclerosis spasticity.
- Nabilone — chemotherapy-induced nausea.
Everything else rides on consumer CBD outside licensed indications. The gap between that narrow evidence core and the vast wellness demand is the market's defining tension — and its central content opportunity: honest, indication-aware authority.
The hard edges
"Commercial cannabidiol oil contaminated with the synthetic cannabinoid AB-FUBINACA given to a pediatric patient." — case report "The presence of THC… through an inaccurately labeled CBD product can cause a positive drug test." — web article
Contamination, mislabelling, delta-8 harms, drug interactions: in an under-regulated product layer, quality assurance is the trust battleground — the brands that prove purity win the anxious middle of the market.
Two countries, in their own words
UK — clinics and caution:
"Just had my follow-up appointment with Alternaleaf and it couldn't have been easier." — review
US — dispensary economics:
"By the time California stacks excise, sales and local taxes, 39 cents of every dollar in an LA dispensary is gone." — YouTube "If you walk into a legal dispensary there's a 75% chance it is losing money." — YouTube